Search Results for "FluMist"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for FluMist. Results 1 to 4 of 4 total matches.
See also: vaccine, influenza
In Brief: FluMist Influenza Vaccine for Self-Administration
The Medical Letter on Drugs and Therapeutics • Oct 28, 2024 (Issue 1714)
In Brief: FluMist Influenza Vaccine for Self-Administration ...
FluMist (AstraZeneca), the live-attenuated intranasal
influenza vaccine that has been available for
years for administration by a healthcare provider
in nonpregnant persons 2-49 years old, has now
been approved by the FDA for self- or caregiver-administration.
It is expected to be available for such
use during the 2025-2026 influenza season. FluMist
is only available through a healthcare provider
this season. It will continue to be available for
administration by a healthcare provider in the future
Med Lett Drugs Ther. 2024 Oct 28;66(1714):174-5 doi:10.58347/tml.2024.1714c | Show Introduction Hide Introduction
Influenza Vaccine for 2024-2025
The Medical Letter on Drugs and Therapeutics • Sep 16, 2024 (Issue 1711)
section).34,35 The live-attenuated intranasal vaccine
(FluMist) should not be used during pregnancy ...
Annual vaccination in the US against influenza A and
B viruses is recommended for everyone ≥6 months
old without a contraindication. Influenza vaccines
available in the US for the 2024-2025 season are
listed in Table 2.
Med Lett Drugs Ther. 2024 Sep 16;66(1711):145-50 doi:10.58347/tml.2024.1711a | Show Introduction Hide Introduction
Comparison Chart: Antiviral Drugs for Seasonal Influenza for 2024-2025 (online only)
The Medical Letter on Drugs and Therapeutics • Dec 09, 2024 (Issue 1717)
164.00 baloxavir influenza antivirals oseltamivir Tamiflu Rapivab zanamivir Relenza FluMist Xofluza ...
View the Comparison Chart: Antiviral Drugs for Seasonal Influenza for 2024-2025
Med Lett Drugs Ther. 2024 Dec 9;66(1717):e1-5 doi:10.58347/tml.2024.1717d | Show Introduction Hide Introduction
Antiviral Drugs for Seasonal Influenza for 2024-2025
The Medical Letter on Drugs and Therapeutics • Dec 09, 2024 (Issue 1717)
(FluMist) could inhibit replication of
the vaccine virus, reducing the vaccine’s effectiveness ...
Influenza is generally a self-limited illness, but
pneumonia, respiratory failure, and death can occur,
especially in persons at increased risk for influenza
complications (see Table 1). Updated information on
influenza activity and antiviral resistance is available
from the CDC at cdc.gov/flu.
Med Lett Drugs Ther. 2024 Dec 9;66(1717):193-8 doi:10.58347/tml.2024.1717a | Show Introduction Hide Introduction